Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259035 · ClinicalTrials.gov registry record · Phase 2
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
A Phase 2 study, sponsored by Canadian Cancer Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03259035 is a Phase 2 study that has completed, run by Canadian Cancer Trials Group. The registered enrollment target is 58 participants.
The verdict
NCT03259035, a Phase 2 study, has completed, sponsored by Canadian Cancer Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
Interventions
- DRUG Capox
- DRUG Folfox Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259035
The ClinicalTrials.gov registry entry for NCT03259035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capox is the first listed.
NCT03259035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259035 about?
NCT03259035 is a clinical study titled "NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer". The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.
What is the current status of trial NCT03259035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2018-06-29. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT03259035?
The interventions under investigation include: Capox (DRUG), Folfox Protocol (DRUG).
Who is sponsoring clinical trial NCT03259035?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.